Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
George Church
Boston Children's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
GC Therapeutics, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Please see attached.
Megakaryocyte Transcription Factor Activation to Enhance In Vitro Platelet Production from Human IPSCs
PUBLIC HEALTH RELEVANCE NARRATIVE Platelet transfusions play life-saving roles for a variety of common health conditions such as for cancer therapy, bone marrow transplantation, bone marrow failure, infections, inherited platelet disorders, and some autoimmune disease, but are limited by frequent shortages due to the short shelf life of donated platelets. Human embryonic and induced pluripotent stem cells (IPSCs) can be coaxed to make platelets in culture dishes, theoretically providing an essentially limitless on-demand supply of tailored platelets, but curren protocols are very inefficient at generating platelets. This proposal seeks to further understand the normal signaling events that cause megakaryocytes (the precursor cell for platelets) to fully mature and produce platelets, and to exploit these findings to increase the efficiency of platelet production from cultured human IPSCs.
Filed on August 06, 2019.
Tell us what you know about George Church's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “George Church”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| George Church | Harvard Medical School | Conflict of Interest | GC Therapeutics | $0 - $4,999 |
| George Church | Harvard Medical School | Conflict of Interest | ReadCoor, Inc. | Value cannot be readily determined |
| George Church | Harvard University | Conflict of Interest | ReadCoor, Inc. | Value cannot be readily determined |
| George Church | Harvard Medical School | Conflict of Interest | GC Therapeutics | Value cannot be readily determined |
| George Church | Harvard Medical School | Conflict of Interest | Editas Medicine | Value cannot be readily determined |
| George Church | Harvard Medical School | Conflict of Interest | ReadCoor, Inc. | Value cannot be readily determined |
| George Church | Harvard Medical School | Conflict of Interest | Twist Bioscience | Value cannot be readily determined |
| George Church | Harvard Medical School | Conflict of Interest | Editas Medicine | $20,000 - $39,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.